After ten hours of testimony about cannabidiol (CBD) from more than 100 stakeholders, two things are clear: The American public has a high desire for CBD products, and too many CBD manufacturers are delivering shoddy goods.
On Friday, FDA Acting Commissioner Ned Sharpless kicked off the agency’s historic first-ever public hearing on CBD by noting that “we’ve seen an explosion of interest in products including CBD, [but] there is much we don’t know.”
Read the full article at Leafly.com